双语新闻：美国批准治疗食物过敏的哮喘药物
The U.S. food and drug agency has approved a medication already used to treat the breathing condition asthma to treat people for food allergies.
美国食品和药物管理局已经批准了一种用于治疗呼吸条件哮喘的药物来治疗食物过敏患者。
On February 16, the United States Food and Drug Administration (or FDA) approved Xolair for a new use. Xolair has become the first medication approved by the FDA to reduce allergic reactions caused by food allergies.
2月16日，美国食品和药物管理局(FDA)批准了Xolair的新用途。Xolair已经成为第一个被FDA批准用于减少食物过敏引起的过敏反应的药物。
Xolair is the brand name, or commercial name, for the drug omalizumab.
Xolair是药物omalizumab的品牌名称或商业名称。
Many people who suffer from allergies — and their families —worry about exposure to things that cause allergic reactions. They might avoid eating at restaurants. They also might avoid social situations in which they might come into contact with something that causes their allergy.
许多患有过敏症的人和他们的家人都担心接触会引起过敏反应的东西。他们可能会避免在餐馆吃饭。他们也可能会避免社交场合，因为他们可能会接触到导致过敏的东西。
Dr. Robert Wood is director of the pediatric allergy division at Johns Hopkins Children's Center. The FDA based its decision on research that Wood led. And the National Institutes of Health supported the allergy study.
罗伯特·伍德博士是约翰·霍普金斯儿童中心儿科过敏部门的主任。FDA的决定是基于Wood领导的研究。美国国立卫生研究院支持这项过敏研究。
One hundred sixty-eight people with allergies to peanuts and at least two other foods took part in the study. It found that 68 percent of the people injected with Xolair were able to have about 600 milligrams of peanut protein without serious problems. That number compares to only six percent of those who received an inactive substance instead of the drug.
168名对花生和至少两种其他食物过敏的人参加了这项研究。研究发现，68%注射了Xolair的人能够摄入约600毫克的花生蛋白，而不会出现严重的问题。相比之下，只有6%的人服用了非活性物质而不是药物。
The results of the study were similar for other allergens, or things that commonly cause allergies, such as tree nuts, milk, eggs, and wheat. Full results from the study are expected to be presented at a meeting and released in a peer-reviewed publication in the near future.
这项研究的结果与其他过敏原或通常引起过敏的东西相似，比如坚果、牛奶、鸡蛋和小麦。该研究的全部结果预计将在不久的将来在一次会议上提出，并在同行评审的出版物中发布。
Wood said: "To have this protection is going to be life changing."
伍德说:“有了这种保护，生活将会改变。”
Wood estimated that 25 to 50 percent of people with food allergies, especially children and young adults, would choose to use Xolair.
伍德估计，25%到50%的食物过敏患者，尤其是儿童和年轻人，会选择使用Xolair。
Patients as young as one year of age with food allergies can take the drug by injection every two to four weeks. This depends on their weight and their body's response to allergens.
一岁以下的食物过敏患者可以每两到四周注射一次这种药物。这取决于他们的体重和身体对过敏原的反应。
People who use Xolair must continue to avoid the foods that cause allergic reactions. These foods are often peanuts, cashews, hazelnuts, walnuts, milk products, and eggs. However, the medication appears to permit exposure to higher amounts of allergy-causing foods without causing major reactions.
使用Xolair的人必须继续避免引起过敏反应的食物。这些食物通常是花生、腰果、榛子、核桃、奶制品和鸡蛋。然而，这种药物似乎允许接触更多的过敏食物而不会引起重大反应。
Until now, doctors have used the drug to treat food allergies although that has not been its officially approved use, said Dr. Ruchi Gupta. Such a second use for a drug is called "off-label." Gupta is director of the Center for Food Allergy & Asthma Research at Northwestern University in Chicago. She welcomed full approval of the product.
鲁奇·古普塔博士说，到目前为止，医生们一直在用这种药物治疗食物过敏，尽管这还没有得到官方批准。这种药物的第二次使用被称为“标签外”。古普塔是芝加哥西北大学食物过敏和哮喘研究中心的主任。她对该产品的全面认可表示欢迎。
Xolair works by blocking the body's natural response to allergens. It is known as a monoclonal antibody. The FDA first approved the drug in 2003. It is used to treat asthma, growths in the nose, and long-term skin problems known as chronic hives.
Xolair通过阻断人体对过敏原的自然反应而起作用。它被称为单克隆抗体。FDA于2003年首次批准了这种药物。它被用来治疗哮喘，鼻子里的生长，以及被称为慢性荨麻疹的长期皮肤问题。
Swiss drug companies Novartis and Roche produce Xolair, and it is distributed by a part of Roche, called Genentech.
瑞士制药公司诺华和罗氏生产Xolair，并由罗氏旗下的基因泰克分销。
The most common side effects of Xolair are injection site reactions and high body temperatures. However, the FDA noted that the drug has also caused joint pain, rash, infections, malignancies, and abnormal laboratory tests.
Xolair最常见的副作用是注射部位反应和体温升高。然而，FDA指出，该药也会引起关节疼痛、皮疹、感染、恶性肿瘤和实验室检测异常。
Xolair also comes with a warning. The treatment itself can cause anaphylaxis, a life-threatening reaction that causes breathing and blood pressure problems. For that reason, the treatment must be started in a health care center with equipment that can deal with such emergencies. In addition, the drug is not approved as an emergency treatment for allergic reactions.
Xolair也有一个警告。治疗本身会引起过敏反应，这是一种危及生命的反应，会导致呼吸和血压问题。出于这个原因，治疗必须在医疗中心开始，那里有可以处理这种紧急情况的设备。此外，该药未被批准作为过敏反应的紧急治疗药物。
Genentech says Xolair is expected to cost about $2,900 a month for children and $5,000 a month for adults. The company said patients usually pay less because their health insurance often pays most of the cost of many drugs.
基因泰克公司表示，Xolair预计儿童每月花费2900美元，成人每月花费5000美元。该公司表示，患者通常支付较少的费用，因为他们的健康保险通常支付许多药物的大部分费用。
美国食品和药物管理局已经批准了一种用于治疗呼吸条件哮喘的药物来治疗食物过敏患者。
On February 16, the United States Food and Drug Administration (or FDA) approved Xolair for a new use. Xolair has become the first medication approved by the FDA to reduce allergic reactions caused by food allergies.
2月16日，美国食品和药物管理局(FDA)批准了Xolair的新用途。Xolair已经成为第一个被FDA批准用于减少食物过敏引起的过敏反应的药物。
Xolair is the brand name, or commercial name, for the drug omalizumab.
Xolair是药物omalizumab的品牌名称或商业名称。
Many people who suffer from allergies — and their families —worry about exposure to things that cause allergic reactions. They might avoid eating at restaurants. They also might avoid social situations in which they might come into contact with something that causes their allergy.
许多患有过敏症的人和他们的家人都担心接触会引起过敏反应的东西。他们可能会避免在餐馆吃饭。他们也可能会避免社交场合，因为他们可能会接触到导致过敏的东西。
Dr. Robert Wood is director of the pediatric allergy division at Johns Hopkins Children's Center. The FDA based its decision on research that Wood led. And the National Institutes of Health supported the allergy study.
罗伯特·伍德博士是约翰·霍普金斯儿童中心儿科过敏部门的主任。FDA的决定是基于Wood领导的研究。美国国立卫生研究院支持这项过敏研究。
One hundred sixty-eight people with allergies to peanuts and at least two other foods took part in the study. It found that 68 percent of the people injected with Xolair were able to have about 600 milligrams of peanut protein without serious problems. That number compares to only six percent of those who received an inactive substance instead of the drug.
168名对花生和至少两种其他食物过敏的人参加了这项研究。研究发现，68%注射了Xolair的人能够摄入约600毫克的花生蛋白，而不会出现严重的问题。相比之下，只有6%的人服用了非活性物质而不是药物。
The results of the study were similar for other allergens, or things that commonly cause allergies, such as tree nuts, milk, eggs, and wheat. Full results from the study are expected to be presented at a meeting and released in a peer-reviewed publication in the near future.
这项研究的结果与其他过敏原或通常引起过敏的东西相似，比如坚果、牛奶、鸡蛋和小麦。该研究的全部结果预计将在不久的将来在一次会议上提出，并在同行评审的出版物中发布。
Wood said: "To have this protection is going to be life changing."
伍德说:“有了这种保护，生活将会改变。”
Wood estimated that 25 to 50 percent of people with food allergies, especially children and young adults, would choose to use Xolair.
伍德估计，25%到50%的食物过敏患者，尤其是儿童和年轻人，会选择使用Xolair。
Patients as young as one year of age with food allergies can take the drug by injection every two to four weeks. This depends on their weight and their body's response to allergens.
一岁以下的食物过敏患者可以每两到四周注射一次这种药物。这取决于他们的体重和身体对过敏原的反应。
People who use Xolair must continue to avoid the foods that cause allergic reactions. These foods are often peanuts, cashews, hazelnuts, walnuts, milk products, and eggs. However, the medication appears to permit exposure to higher amounts of allergy-causing foods without causing major reactions.
使用Xolair的人必须继续避免引起过敏反应的食物。这些食物通常是花生、腰果、榛子、核桃、奶制品和鸡蛋。然而，这种药物似乎允许接触更多的过敏食物而不会引起重大反应。
Until now, doctors have used the drug to treat food allergies although that has not been its officially approved use, said Dr. Ruchi Gupta. Such a second use for a drug is called "off-label." Gupta is director of the Center for Food Allergy & Asthma Research at Northwestern University in Chicago. She welcomed full approval of the product.
鲁奇·古普塔博士说，到目前为止，医生们一直在用这种药物治疗食物过敏，尽管这还没有得到官方批准。这种药物的第二次使用被称为“标签外”。古普塔是芝加哥西北大学食物过敏和哮喘研究中心的主任。她对该产品的全面认可表示欢迎。
Xolair works by blocking the body's natural response to allergens. It is known as a monoclonal antibody. The FDA first approved the drug in 2003. It is used to treat asthma, growths in the nose, and long-term skin problems known as chronic hives.
Xolair通过阻断人体对过敏原的自然反应而起作用。它被称为单克隆抗体。FDA于2003年首次批准了这种药物。它被用来治疗哮喘，鼻子里的生长，以及被称为慢性荨麻疹的长期皮肤问题。
Swiss drug companies Novartis and Roche produce Xolair, and it is distributed by a part of Roche, called Genentech.
瑞士制药公司诺华和罗氏生产Xolair，并由罗氏旗下的基因泰克分销。
The most common side effects of Xolair are injection site reactions and high body temperatures. However, the FDA noted that the drug has also caused joint pain, rash, infections, malignancies, and abnormal laboratory tests.
Xolair最常见的副作用是注射部位反应和体温升高。然而，FDA指出，该药也会引起关节疼痛、皮疹、感染、恶性肿瘤和实验室检测异常。
Xolair also comes with a warning. The treatment itself can cause anaphylaxis, a life-threatening reaction that causes breathing and blood pressure problems. For that reason, the treatment must be started in a health care center with equipment that can deal with such emergencies. In addition, the drug is not approved as an emergency treatment for allergic reactions.
Xolair也有一个警告。治疗本身会引起过敏反应，这是一种危及生命的反应，会导致呼吸和血压问题。出于这个原因，治疗必须在医疗中心开始，那里有可以处理这种紧急情况的设备。此外，该药未被批准作为过敏反应的紧急治疗药物。
Genentech says Xolair is expected to cost about $2,900 a month for children and $5,000 a month for adults. The company said patients usually pay less because their health insurance often pays most of the cost of many drugs.
基因泰克公司表示，Xolair预计儿童每月花费2900美元，成人每月花费5000美元。该公司表示，患者通常支付较少的费用，因为他们的健康保险通常支付许多药物的大部分费用。
